Zoetis (NYSE:ZTS) Issues FY 2025 Earnings Guidance

Zoetis (NYSE:ZTS) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 6.000-6.100 for the period, compared to the consensus earnings per share estimate of 6.300. The company issued revenue guidance of $9.2 billion-$9.4 billion, compared to the consensus revenue estimate of $9.6 billion.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ZTS. UBS Group began coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Morgan Stanley lowered their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Stifel Nicolaus cut their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. Finally, Piper Sandler dropped their price objective on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a report on Monday. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $214.00.

Zoetis Stock Performance

Zoetis stock traded down $9.67 during midday trading on Thursday, hitting $164.21. The stock had a trading volume of 9,087,352 shares, compared to its average volume of 2,842,682. The firm’s fifty day moving average is $169.08 and its two-hundred day moving average is $179.08. The company has a market capitalization of $74.09 billion, a PE ratio of 30.90, a P/E/G ratio of 2.77 and a beta of 0.90. Zoetis has a 52-week low of $144.80 and a 52-week high of $200.53. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. On average, research analysts forecast that Zoetis will post 5.9 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.22%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is 37.59%.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.16% of the stock is currently owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.